肺高血圧症新規治療薬のポテンシャル
Saved in:
| Published in | 血管 Vol. 42; no. 3; pp. 1 - 8 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本心脈管作動物質学会
13.12.2019
|
| Online Access | Get full text |
| ISSN | 0911-4637 2759-2286 |
| DOI | 10.60370/jjcircres.42.3_1 |
Cover
| Author | 福本, 義弘 |
|---|---|
| Author_xml | – sequence: 1 fullname: 福本, 義弘 organization: 久留米大学医学部内科学講座 心臓・血管内科部門 |
| BookMark | eNo9j8tKw0AYhQepYKx9AB8icTLXzLIUb1Bwo-vh72SiCbVK0o07TUCX7qqCLkTQRUVEF4I-zmAb30JF6eacDw58cBZRY3AwsAgthzgQmEq8kmUmzU1ui4CRgOpwDnlEcuUTEokG8rAKQ58JKhdQqyjSHuaMCC5Y5CFal-9f48v69vjz-mF6cTYZPdf355OXj-lVWY8e3cmTq25cdeqqV1e-uerOVeMlNJ9Av7Ct_26inbXV7c6G391a3-y0u35GMAc_SuLEWEsIERATLq0FmfRYqDBWPxzLRHKgwBQnEQVKFWDD4khiZXgsY0GbqP3nzYoh7Fp9mKf7kB9pyIep6Vs9e60Z0fQ3wtlm9iDXGdBv-udotg |
| ContentType | Journal Article |
| Copyright | 2019 日本心脈管作動物質学会 |
| Copyright_xml | – notice: 2019 日本心脈管作動物質学会 |
| DOI | 10.60370/jjcircres.42.3_1 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2759-2286 |
| EndPage | 8 |
| ExternalDocumentID | article_jjcircres_42_3_42_1_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS |
| ID | FETCH-LOGICAL-j205a-8fdfcee2226ad257eea7fb419009eead7f75a3a495283a339a0c4d8709c5d7d63 |
| ISSN | 0911-4637 |
| IngestDate | Wed Sep 03 06:31:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 3 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j205a-8fdfcee2226ad257eea7fb419009eead7f75a3a495283a339a0c4d8709c5d7d63 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjcircres/42/3/42_1/_article/-char/ja |
| PageCount | 8 |
| ParticipantIDs | jstage_primary_article_jjcircres_42_3_42_1_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2019/12/13 |
| PublicationDateYYYYMMDD | 2019-12-13 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019/12/13 day: 13 |
| PublicationDecade | 2010 |
| PublicationTitle | 血管 |
| PublicationYear | 2019 |
| Publisher | 日本心脈管作動物質学会 |
| Publisher_xml | – name: 日本心脈管作動物質学会 |
| References | Mainguy V, Maltais F, Saey D, Gagnon P, MartelS, Simon M and Provencher S. Peripheral muscledysfunction in idiopathic pulmonary arterialhypertension. Thorax. 2010;65:113-7. Oshima K and Oka M. Sex hormones. FukumotoY, ed, Diagnosis and Treatment of PulmonaryHypertension Springer, Singapore. 2017:55-65. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA,Cool CD, Voelkel NF, McMurtry IF and Oka M.Formation of plexiform lesions in experimentalsevere pulmonary arterial hypertension.Circulation. 2010;121:2747-54. Andersen S, Axelsen JB, Ringgaard S, NyengaardJR, Hyldebrandt JA, Bogaard HJ, de Man FS,Nielsen-Kudsk JE and Andersen A. Effects ofcombined angiotensin II receptor antagonism andneprilysin inhibition in experimental pulmonaryhypertension and right ventricular failure. Int JCardiol. 2019;293:203-210. Hashimoto-Kataoka T, Hosen N, SonobeT, Arita Y, Yasui T, Masaki T, Minami M,Inagaki T, Miyagawa S, Sawa Y, Murakami M,Kumanogoh A, Yamauchi-Takihara K, OkumuraM, Kishimoto T, Komuro I, Shirai M, SakataY and Nakaoka Y. Interleukin-6/interleukin-21signaling axis is critical in the pathogenesis ofpulmonary arterial hypertension. Proc Natl AcadSci U S A. 2015;112:E2677-86. Simonneau G, Montani D, Celermajer DS, DentonCP, Gatzoulis MA, Krowka M, Williams PG andSouza R. Haemodynamic definitions and updatedclinical classification of pulmonary hypertension.Eur Respir J. 2019;53. Fukumoto Y, Yamada N, Matsubara H,Mizoguchi M, Uchino K, Yao A, Kihara Y,Kawano M, Watanabe H, Takeda Y, Adachi T,Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y,Fukuda K, Nakano T and Shimokawa H. Doubleblind, placebo-controlled clinical trial with arho-kinase inhibitor in pulmonary arterialhypertension. Circ J. 2013;77:2619-25. Sutendra G and Michelakis ED. The metabolicbasis of pulmonary arterial hypertension. CellMetab. 2014;19:558-73. Malenfant S, Potus F, Fournier F, Breuils-BonnetS, Pflieger A, Bourassa S, Tremblay E, NehmeB, Droit A, Bonnet S and Provencher S. Skeletalmuscle proteomic signature and metabolicimpairment in pulmonary hypertension. J MolMed (Berl). 2015;93:573-84. Babicheva A, McDermott KM, Williams SC, YeeAM, Dash S, Rodriquez M, Ingabire N, Makino Aand Yuan JX. Pathogenic and therapeutic role ofmicroRNA in pulmonary arterial hypertension.Fukumoto Y, ed, Diagnosis and Treatment ofPulmonary Hypertension Springer, Singapore.2017:31-54. Liu A, Hacker T, Eickhoff JC and CheslerNC. Estrogen Preserves Pulsatile PulmonaryArterial Hemodynamics in Pulmonary ArterialHypertension. Ann Biomed Eng. 2017;45:632-643. Price LC, Caramori G, Perros F, Meng C,Gambaryan N, Dorfmuller P, Montani D,Casolari P, Zhu J, Dimopoulos K, Shao D, GirerdB, Mumby S, Proudfoot A, Griffiths M, Papi A,Humbert M, Adcock IM and Wort SJ. Nuclearfactor kappa-B is activated in the pulmonaryvessels of patients with end-stage idiopathicpulmonary arterial hypertension. PLoS One.2013;8:e75415. Hayden MS and Ghosh S. Shared principles inNF-kappaB signaling. Cell. 2008;132:344-62. Hoeper MM, Barst RJ, Bourge RC, FeldmanJ, Frost AE, Galie N, Gomez-Sanchez MA,Grimminger F, Grunig E, Hassoun PM, MorrellNW, Peacock AJ, Satoh T, Simonneau G,Tapson VF, Torres F, Lawrence D, Quinn DAand Ghofrani HA. Imatinib mesylate as add-ontherapy for pulmonary arterial hypertension:results of the randomized IMPRES study.Circulation. 2013;127:1128-38. Fukumoto Y, Matoba T, Ito A, Tanaka H, KishiT, Hayashidani S, Abe K, Takeshita A andShimokawa H. Acute vasodilator effects of a Rhokinase inhibitor, fasudil, in patients with severepulmonary hypertension. Heart. 2005;91:391-2. Sato H, Sugimura K, Miura M, Konno R, KozuK, Yaoita N, Shimizu T, Yamamoto S, Aoki T,Tatebe S, Satoh K and Shimokawa H. BeneficialEffects of Imatinib in a Patient with SuspectedPulmonary Veno-Occlusive Disease. Tohoku J ExpMed. 2019;247:69-73. Sporn MB, Liby KT, Yore MM, Fu L, LopchukJM and Gribble GW. New synthetic triterpenoids:potent agents for prevention and treatmentof tissue injury caused by inflammatory andoxidative stress. J Nat Prod. 2011;74:537-45. Shimokawa H and Takeshita A. Rho-kinase is animportant therapeutic target in cardiovascularmedicine. Arterioscler Thromb Vasc Biol.2005;25:1767-75. Guerra G, Perrotta F and Testa G. CirculatingEndothelial Progenitor Cells Biology andRegenerative Medicine in Pulmonary VascularDiseases. Curr Pharm Biotechnol. 2018;19:700-707 Hobbs AJ, Moyes AJ, Baliga RS, Ghedia D,Ochiel R, Sylvestre Y, Dore CJ, ChowdhuryK, Maclagan K, Quartly HL, Sofat R, Smit A,Schreiber BE, Coghlan GJ and MacAllister RJ.Neprilysin inhibition for pulmonary arterialhypertension: a randomized, double-blind,placebo-controlled, proof-of-concept trial. Br JPharmacol. 2019;176:1251-1267. Xing Y, Zheng X, Fu Y, Qi J, Li M, Ma M,Wang S, Li S and Zhu D. Long Noncoding RNAMaternally Expressed Gene 3 Contributes toHypoxic Pulmonary Hypertension. Mol Ther.2019. Yamamoto K, Nishimura R, Kato F, Naito A,Suda R, Sekine A, Jujo T, Shigeta A, SakaoS, Tanabe N and Tatsumi K. Protective roleof endothelial progenitor cells stimulated byriociguat in chronic thromboembolic pulmonaryhypertension. Int J Cardiol. 2019. Durham GA and Palmer TM. Is there a role forprostanoid-mediated inhibition of IL-6 transsignalling in the management of pulmonaryarterial hypertension? Biochem Soc Trans.2019;47:1143-1156. Batt J, Ahmed SS, Correa J, Bain A and GrantonJ. Skeletal muscle dysfunction in idiopathicpulmonary arterial hypertension. Am J RespirCell Mol Biol. 2014;50:74-86. Leuchte HH, Prechtl C, Callegari J, Meis T,Haziraj S, Bevec D and Behr J. Augmentation ofthe effects of vasoactive intestinal peptide aerosolon pulmonary hypertension via coapplication ofa neutral endopeptidase 24.11 inhibitor. Am JPhysiol Lung Cell Mol Physiol. 2015;308:L563-8. Babicheva A, Ayon RJ, Zhao T, Ek Vitorin JF,Pohl NM, Yamamura A, Yamamura H, QuintonBA, Ba M, Wu L, Ravellette KS, Rahimi S,Balistrieri F, Harrington A, Vanderpool RR,Thistlethwaite PA, Makino A and Yuan JX.MicroRNA-mediated Downregulation of K(+)Channels in Pulmonary Arterial Hypertension.Am J Physiol Lung Cell Mol Physiol. 2019. Do e Z, Fukumoto Y, Takaki A, Tawara S,Ohashi J, Nakano M, Tada T, Saji K, Sugimura K,Fujita H, Hoshikawa Y, Nawata J, Kondo T andShimokawa H. Evidence for Rho-kinase activationin patients with pulmonary arterial hypertension.Circ J. 2009;73:1731-9. Hirano K. The unique property of the pulmonaryartery regarding the smooth muscle effects ofproteinase-activated receptor 1: The possiblecontribution to the pathogenesis of pulmonaryhypertension. Fukumoto Y, ed, Diagnosis andTreatment of Pulmonary Hypertension Springer,Singapore. 2017:77-87. Kuwabara Y, Tanaka-Ishikawa M, Abe K,Hirano M, Hirooka Y, Tsutsui H, Sunagawa Kand Hirano K. Proteinase-activated receptor 1antagonism ameliorates experimental pulmonaryhypertension. Cardiovasc Res. 2019;115:1357-1368. |
| References_xml | – reference: Shimokawa H and Takeshita A. Rho-kinase is animportant therapeutic target in cardiovascularmedicine. Arterioscler Thromb Vasc Biol.2005;25:1767-75. – reference: Hayden MS and Ghosh S. Shared principles inNF-kappaB signaling. Cell. 2008;132:344-62. – reference: Kuwabara Y, Tanaka-Ishikawa M, Abe K,Hirano M, Hirooka Y, Tsutsui H, Sunagawa Kand Hirano K. Proteinase-activated receptor 1antagonism ameliorates experimental pulmonaryhypertension. Cardiovasc Res. 2019;115:1357-1368. – reference: Hashimoto-Kataoka T, Hosen N, SonobeT, Arita Y, Yasui T, Masaki T, Minami M,Inagaki T, Miyagawa S, Sawa Y, Murakami M,Kumanogoh A, Yamauchi-Takihara K, OkumuraM, Kishimoto T, Komuro I, Shirai M, SakataY and Nakaoka Y. Interleukin-6/interleukin-21signaling axis is critical in the pathogenesis ofpulmonary arterial hypertension. Proc Natl AcadSci U S A. 2015;112:E2677-86. – reference: Yamamoto K, Nishimura R, Kato F, Naito A,Suda R, Sekine A, Jujo T, Shigeta A, SakaoS, Tanabe N and Tatsumi K. Protective roleof endothelial progenitor cells stimulated byriociguat in chronic thromboembolic pulmonaryhypertension. Int J Cardiol. 2019. – reference: Fukumoto Y, Matoba T, Ito A, Tanaka H, KishiT, Hayashidani S, Abe K, Takeshita A andShimokawa H. Acute vasodilator effects of a Rhokinase inhibitor, fasudil, in patients with severepulmonary hypertension. Heart. 2005;91:391-2. – reference: Price LC, Caramori G, Perros F, Meng C,Gambaryan N, Dorfmuller P, Montani D,Casolari P, Zhu J, Dimopoulos K, Shao D, GirerdB, Mumby S, Proudfoot A, Griffiths M, Papi A,Humbert M, Adcock IM and Wort SJ. Nuclearfactor kappa-B is activated in the pulmonaryvessels of patients with end-stage idiopathicpulmonary arterial hypertension. PLoS One.2013;8:e75415. – reference: Batt J, Ahmed SS, Correa J, Bain A and GrantonJ. Skeletal muscle dysfunction in idiopathicpulmonary arterial hypertension. Am J RespirCell Mol Biol. 2014;50:74-86. – reference: Fukumoto Y, Yamada N, Matsubara H,Mizoguchi M, Uchino K, Yao A, Kihara Y,Kawano M, Watanabe H, Takeda Y, Adachi T,Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y,Fukuda K, Nakano T and Shimokawa H. Doubleblind, placebo-controlled clinical trial with arho-kinase inhibitor in pulmonary arterialhypertension. Circ J. 2013;77:2619-25. – reference: Andersen S, Axelsen JB, Ringgaard S, NyengaardJR, Hyldebrandt JA, Bogaard HJ, de Man FS,Nielsen-Kudsk JE and Andersen A. Effects ofcombined angiotensin II receptor antagonism andneprilysin inhibition in experimental pulmonaryhypertension and right ventricular failure. Int JCardiol. 2019;293:203-210. – reference: Abe K, Toba M, Alzoubi A, Ito M, Fagan KA,Cool CD, Voelkel NF, McMurtry IF and Oka M.Formation of plexiform lesions in experimentalsevere pulmonary arterial hypertension.Circulation. 2010;121:2747-54. – reference: Sporn MB, Liby KT, Yore MM, Fu L, LopchukJM and Gribble GW. New synthetic triterpenoids:potent agents for prevention and treatmentof tissue injury caused by inflammatory andoxidative stress. J Nat Prod. 2011;74:537-45. – reference: Hirano K. The unique property of the pulmonaryartery regarding the smooth muscle effects ofproteinase-activated receptor 1: The possiblecontribution to the pathogenesis of pulmonaryhypertension. Fukumoto Y, ed, Diagnosis andTreatment of Pulmonary Hypertension Springer,Singapore. 2017:77-87. – reference: Babicheva A, Ayon RJ, Zhao T, Ek Vitorin JF,Pohl NM, Yamamura A, Yamamura H, QuintonBA, Ba M, Wu L, Ravellette KS, Rahimi S,Balistrieri F, Harrington A, Vanderpool RR,Thistlethwaite PA, Makino A and Yuan JX.MicroRNA-mediated Downregulation of K(+)Channels in Pulmonary Arterial Hypertension.Am J Physiol Lung Cell Mol Physiol. 2019. – reference: Hobbs AJ, Moyes AJ, Baliga RS, Ghedia D,Ochiel R, Sylvestre Y, Dore CJ, ChowdhuryK, Maclagan K, Quartly HL, Sofat R, Smit A,Schreiber BE, Coghlan GJ and MacAllister RJ.Neprilysin inhibition for pulmonary arterialhypertension: a randomized, double-blind,placebo-controlled, proof-of-concept trial. Br JPharmacol. 2019;176:1251-1267. – reference: Sato H, Sugimura K, Miura M, Konno R, KozuK, Yaoita N, Shimizu T, Yamamoto S, Aoki T,Tatebe S, Satoh K and Shimokawa H. BeneficialEffects of Imatinib in a Patient with SuspectedPulmonary Veno-Occlusive Disease. Tohoku J ExpMed. 2019;247:69-73. – reference: Durham GA and Palmer TM. Is there a role forprostanoid-mediated inhibition of IL-6 transsignalling in the management of pulmonaryarterial hypertension? Biochem Soc Trans.2019;47:1143-1156. – reference: Mainguy V, Maltais F, Saey D, Gagnon P, MartelS, Simon M and Provencher S. Peripheral muscledysfunction in idiopathic pulmonary arterialhypertension. Thorax. 2010;65:113-7. – reference: Sutendra G and Michelakis ED. The metabolicbasis of pulmonary arterial hypertension. CellMetab. 2014;19:558-73. – reference: Oshima K and Oka M. Sex hormones. FukumotoY, ed, Diagnosis and Treatment of PulmonaryHypertension Springer, Singapore. 2017:55-65. – reference: Xing Y, Zheng X, Fu Y, Qi J, Li M, Ma M,Wang S, Li S and Zhu D. Long Noncoding RNAMaternally Expressed Gene 3 Contributes toHypoxic Pulmonary Hypertension. Mol Ther.2019. – reference: Babicheva A, McDermott KM, Williams SC, YeeAM, Dash S, Rodriquez M, Ingabire N, Makino Aand Yuan JX. Pathogenic and therapeutic role ofmicroRNA in pulmonary arterial hypertension.Fukumoto Y, ed, Diagnosis and Treatment ofPulmonary Hypertension Springer, Singapore.2017:31-54. – reference: Guerra G, Perrotta F and Testa G. CirculatingEndothelial Progenitor Cells Biology andRegenerative Medicine in Pulmonary VascularDiseases. Curr Pharm Biotechnol. 2018;19:700-707 – reference: Liu A, Hacker T, Eickhoff JC and CheslerNC. Estrogen Preserves Pulsatile PulmonaryArterial Hemodynamics in Pulmonary ArterialHypertension. Ann Biomed Eng. 2017;45:632-643. – reference: Malenfant S, Potus F, Fournier F, Breuils-BonnetS, Pflieger A, Bourassa S, Tremblay E, NehmeB, Droit A, Bonnet S and Provencher S. Skeletalmuscle proteomic signature and metabolicimpairment in pulmonary hypertension. J MolMed (Berl). 2015;93:573-84. – reference: Leuchte HH, Prechtl C, Callegari J, Meis T,Haziraj S, Bevec D and Behr J. Augmentation ofthe effects of vasoactive intestinal peptide aerosolon pulmonary hypertension via coapplication ofa neutral endopeptidase 24.11 inhibitor. Am JPhysiol Lung Cell Mol Physiol. 2015;308:L563-8. – reference: Do e Z, Fukumoto Y, Takaki A, Tawara S,Ohashi J, Nakano M, Tada T, Saji K, Sugimura K,Fujita H, Hoshikawa Y, Nawata J, Kondo T andShimokawa H. Evidence for Rho-kinase activationin patients with pulmonary arterial hypertension.Circ J. 2009;73:1731-9. – reference: Simonneau G, Montani D, Celermajer DS, DentonCP, Gatzoulis MA, Krowka M, Williams PG andSouza R. Haemodynamic definitions and updatedclinical classification of pulmonary hypertension.Eur Respir J. 2019;53. – reference: Hoeper MM, Barst RJ, Bourge RC, FeldmanJ, Frost AE, Galie N, Gomez-Sanchez MA,Grimminger F, Grunig E, Hassoun PM, MorrellNW, Peacock AJ, Satoh T, Simonneau G,Tapson VF, Torres F, Lawrence D, Quinn DAand Ghofrani HA. Imatinib mesylate as add-ontherapy for pulmonary arterial hypertension:results of the randomized IMPRES study.Circulation. 2013;127:1128-38. |
| SSID | ssib054265648 ssib002822034 ssib058493454 ssib056835060 ssib000940426 ssib059239749 ssib041933056 |
| Score | 2.2103755 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 1 |
| Title | 肺高血圧症新規治療薬のポテンシャル |
| URI | https://www.jstage.jst.go.jp/article/jjcircres/42/3/42_1/_article/-char/ja |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 血管, 2019/12/13, Vol.42(3), pp.1-8 |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2759-2286 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib056835060 issn: 0911-4637 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV29i9RAFA_L2diIouI3Vzhl1iTzbTfZzXIIZ3UH14V8gluccu41FqK7oKXdqaCFCFqciGgh6J8TvFv_BDvfm2Q3Qa7wtAlv37z5ePMmmd-bnXnjONdpWuRUM-UWAS7dMBa4KQBxN1W4ysBkmdgApuu3xdomu7XFt3q9X51dS7uTtJ89OPJcyb9YFXhgVzwlewzLLgsFBtBgX3iCheH5VzYmkSIqIKEhkSYmJFohx_i4fSHiRA-IkSSSREsCPn8kiBYk9KyMIGqEnBCyh1ZGY1GQBDJmQCIKGJOYyBKU6GFDKNEQIbUEZJcNx9AFEXYhb6dJEgs0SyNbxqIh2NgBGhy5IYhpVCEckPr66MXKhG-vVagPltqxZPNCObwtBPONsCHYPYCV1bJmEjESDlEMZBR0GMckpW1tCnUyBpPMEBuGwlC_6S5n-uALizqATL-wvEBy7cIQFN2vPQs6o5p2Pt1-FwMcNbkIj0rcjjkeZ3d2ANLf77OgT2O_nUmX-xubEREvRWMWxBQffrxIw1N18Rig_YlACoGXb6w_jDrIl6F32_WMA6-N5Md8XIhqwyBxkOWi9Wy5gFfNaz1fgJmashY5csD14EnWkSibnqv_87da3vhTR8BnY_BWFjsdLfjaOO2carymVVMrdcbpjZOzDp1Pv_3cfzF_8-jHq_eHz58e7H2av3t28Pn74cvpfO9D9fhjNXtdzZ5Usy_V9Gs1e1vN9s85m6NoY7DmNneAuOPA44mryrwEHAcoViQ5TC9FkcgyBfWhh4DOZSl5QhNw8wEnJ5TqxMtYDpOQznguc0HPOyvbd7eLC85qkpSpwD1JPM2YlygloIfTTBQCfjKhLzo3ax3je3Wgl_gYZrz0P5kvOyfb9-eKszLZ2S2uAtadpNfsqPgNOu2OQA |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%82%BA%E9%AB%98%E8%A1%80%E5%9C%A7%E7%97%87%E6%96%B0%E8%A6%8F%E6%B2%BB%E7%99%82%E8%96%AC%E3%81%AE%E3%83%9D%E3%83%86%E3%83%B3%E3%82%B7%E3%83%A3%E3%83%AB&rft.jtitle=%E8%A1%80%E7%AE%A1&rft.au=%E7%A6%8F%E6%9C%AC%2C+%E7%BE%A9%E5%BC%98&rft.date=2019-12-13&rft.pub=%E6%97%A5%E6%9C%AC%E5%BF%83%E8%84%88%E7%AE%A1%E4%BD%9C%E5%8B%95%E7%89%A9%E8%B3%AA%E5%AD%A6%E4%BC%9A&rft.issn=0911-4637&rft.eissn=2759-2286&rft.volume=42&rft.issue=3&rft.spage=1&rft.epage=8&rft_id=info:doi/10.60370%2Fjjcircres.42.3_1&rft.externalDocID=article_jjcircres_42_3_42_1_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0911-4637&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0911-4637&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0911-4637&client=summon |